Tuesday, Sep 27, 2005
South San Francisco, Calif. -- September 27, 2005 --Genentech, Inc. (NYSE: DNA) today provided information on the pending reexamination of the Cabilly, et al. U.S. Patent No. 6,331,415 ('415 patent), which was ordered by the U.S. Patent Office on July 7, 2005. Genentech had previously disclosed the existence of the reexamination in its Quarterly Report on Form 10-Q for the period ended June 30, 2005, filed with the Securities and Exchange Commission on August 2, 2005.
On September 13, 2005, the U.S. Patent Office issued an initial Office action rejecting the claims of the '415 or Cabilly patent. This action is a routine and expected next step in the reexamination procedure. Genentech plans to respond within 60 days from the mailing date of the action.
The Office action originates from a request for reexamination of the '415 or Cabilly patent filed on May 13, 2005 by a third party.
A final resolution of the reexamination may take from several months to several years. The Cabilly patent remains valid and enforceable while the reexamination is pending.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.